Strategic M&A
First written in FY2016. 12 of 22 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
Daicel moved to the "Worse" side of this theme in 2022.
7 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Under Operation-Ⅱ (New Daicel), the company will work to expand into adjacent areas of existing businesses through M&A and alliances, restructure existing businesses, and fundamentally review its joint ventures.」
M&A and alliances continue to be positioned as means of expanding into areas adjacent to existing businesses and restructuring businesses. - 2026-05-22AdvancedEarnings presentation
「ハイエンド樹脂のラインナップ拡充と他社協業・M& A積極展開」
戦略的M&Aの活用について、ハイエンド樹脂の拡充と他社協業・M&Aを成長手段として明示した。 - FY2025AdvancedAnnual report
「On 28 March 2025, we entered into a share transfer agreement with 三菱ケミカル(株) and acquired all shares of 富山フィルタートウ(株).」
As part of its strategic M&A, the company acquired all shares of 富山フィルタートウ株式会社 under a share transfer agreement with 三菱ケミカル株式会社. - FY2024-Q3AdvancedAnnual report
「Our consolidated subsidiary ポリプラスチックス㈱ entered into a share transfer agreement with Ticona LLC dated 15 December 2023 and additionally acquired all issued shares of our consolidated subsidiary ピーティーエム・ホールディングス㈱ held by Ticona LLC. As a result, ポリプラスチックス㈱’s equity ownership ratio in ピーティーエム・ホールディングス㈱ was 71% as of the end of December 2023.」
As part of its strategic M&A, ポリプラスチックス additionally acquired shares of ピーティーエム・ホールディングス, bringing its equity ownership ratio to 71% as of the end of December 2023. - FY2024-Q1WorsenedAnnual report
「The Life Sciences business reported lower revenue, despite strong sales of chiral-related products, due to the impact of selling a subsidiary engaged in contract pharmaceutical development and manufacturing at the end of the previous fiscal year.」
The sale of the subsidiary engaged in contract pharmaceutical development and manufacturing appeared in the current-quarter results as lower revenue in the Life Sciences business. - FY2023WorsenedAnnual report
「Daicel Safety Systems Korea, Inc. and two other companies have been excluded from the scope of consolidation because liquidation procedures are under way and their materiality has declined. Lomapharm GmbH has also been excluded from the scope of consolidation because its shares were sold.」
The company disclosed the sale of shares in Lomapharm GmbH, which had been acquired and consolidated through strategic M&A, and the liquidation procedures for Daicel Safety Systems Korea and other companies. - FY2022-Q3WorsenedAnnual report
「Goodwill based on excess earning power had been recognized in connection with the acquisition of consolidated subsidiary Lomapharm GmbH. However, because declining profitability made recovery of the investment amount difficult, the entire unamortized balance has been recognized as an impairment loss.」
For Lomapharm GmbH, acquired through strategic M&A, declining profitability made recovery of the investment amount difficult, and the entire unamortized goodwill balance was recognized as an impairment loss. - FY2022-Q2AdvancedAnnual report
「We entered into a share transfer agreement with JNC株式会社 dated 30 September 2021 and additionally acquired all shares of our consolidated subsidiary 協同酢酸株式会社 held by JNC株式会社. As a result, our equity ownership ratio in 協同酢酸株式会社 was 92% as of the end of September 2021.」
As part of its strategic M&A, the company additionally acquired all shares of 協同酢酸株式会社 held by JNC株式会社, raising its equity ownership ratio to 92%. - FY2021AdvancedAnnual report
「To maximize synergies from making ポリプラスチックス a wholly owned subsidiary, we newly established the Performance Materials Business Headquarters. The president of ポリプラスチックス will concurrently serve as head of the headquarters as our senior executive officer, and we will work to strengthen the Group’s resin business as a whole. Specifically, we will accelerate ポリプラスチックス’ global expansion, including investment to increase production to capture future demand and expanded sales in Europe and North America; realize cost-reduction synergies, including accelerating the rollout of Daicel-style production innovation and improving the efficiency of indirect functions; and maximize Group synergies, including using ポリプラスチックス’ marketing capabilities, sharing R&D resources, and improving and upgrading existing businesses through measures such as improving catalyst efficiency. We expect EBITDA synergies of ¥20 billion by fiscal 2025.」
As an integration measure following the acquisition of ポリプラスチックス as a wholly owned subsidiary, the company presented a plan to establish a dedicated headquarters and combine global expansion, cost reductions and R&D collaboration, with expected EBITDA synergies of ¥20 billion by fiscal 2025. - FY2021-Q2AdvancedAnnual report
「We entered into an agreement to acquire all shares of our consolidated subsidiary ポリプラスチックス株式会社 held by Celanese Corporation through its subsidiary, and completed the share acquisition on 9 October 2020. The post-acquisition voting rights ratio was 100%.」
As part of its strategic M&A, the company completed the additional acquisition of 45% of the common shares of ポリプラスチックス株式会社, which had been at the agreement stage, on 9 October 2020, making it a wholly owned subsidiary. - FY2021-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 3 July 2020, we resolved to make our consolidated subsidiary ポリプラスチックス株式会社 a wholly owned subsidiary by additionally acquiring 45% of its common shares, and on 20 July 2020 entered into an agreement relating to the share acquisition.」
As part of its strategic M&A, the company proceeded to a resolution and agreement to additionally acquire 45% of the common shares of ポリプラスチックス and make it a wholly owned subsidiary. The purchase price is US$1,575 million, subject to approval by competition authorities in each country and other conditions. - FY2020AdvancedAnnual report
「In January 2020, we acquired shares issued by パイクリスタル㈱ and made it a subsidiary.」
As part of its strategic M&A, the company acquired shares of パイクリスタル㈱ and made it a subsidiary, bringing in a business platform related to AI and IoT. - FY2020-Q3Cited as achievedAnnual report
「The Other segment reported higher revenue, partly because the overseas pharmaceutical formulation business acquired in the previous fiscal year contributed to results.」
The company reported that the overseas pharmaceutical formulation company acquired in the previous fiscal year contributed to higher revenue. - FY2020-Q1AdvancedAnnual report
「The Other segment reported higher revenue, partly because the overseas pharmaceutical formulation business acquired in the previous fiscal year contributed to results.」
The acquisition of an overseas pharmaceutical formulation company in the previous fiscal year contributed to higher revenue in the current quarter. - FY2019AdvancedAnnual report
「Through equity investments, Lomapharm GmbH and Biodiscovery LLC (commonly known as Arbor Biosciences) have each been included in the scope of consolidation from the current consolidated fiscal year.」
Equity investments in Lomapharm and Biodiscovery LLC added businesses to the scope of consolidation. - FY2019-Q3RestatedAnnual report
「Effective 1 August 2018, we acquired Lomapharm, a German contract pharmaceutical development and manufacturing company comprising LOMA Holding GmbH, Lomapharm Rudolf Lohmann GmbH KG and Lomapharm Verwaltungs GmbH. Going forward, we will work closely with Lomapharm to accelerate growth in the medical field, which we have positioned as one of the pillars of our new business areas.」
The policy of accelerating growth in the medical field through the acquisition of Lomapharm continues. - FY2019-Q2AdvancedAnnual report
「Effective 1 August 2018, we acquired Lomapharm, a German contract pharmaceutical development and manufacturing company comprising LOMA Holding GmbH, Lomapharm Rudolf Lohmann GmbH KG and Lomapharm Verwaltungs GmbH. Going forward, we will work closely with Lomapharm to accelerate growth in the medical field, which we have positioned as one of the pillars of our new business areas.」
As part of its strategic M&A, the company acquired three German companies of Lomapharm to accelerate growth in the medical field. - FY2018RestatedAnnual report
「We will also actively pursue planned collaboration with external parties and M&A in existing business areas to accelerate growth.」
The policy of using collaboration with external parties and M&A as means of accelerating growth continues, including in existing business areas. - FY2018-Q3RestatedAnnual report
「With respect to creating new businesses, we will concentrate and invest management resources in the five “new business unit candidates” identified in the medical and healthcare and electronics fields, which are priority areas.」
There has been no change to the growth investment policy, including M&A, and continued concentration of resources on R&D and new businesses has been indicated. - FY2017RaisedAnnual report
「We will also actively pursue planned collaboration with external parties and M&A in existing business areas to accelerate growth.」
The policy of using M&A has been extended under the new medium-term plan to include existing business areas, with an active execution policy. - FY2017-Q2AdvancedAnnual report
「Date of business combination: 30 September 2016 The shares held by non-controlling shareholders were acquired to strengthen business operations by making the company a wholly owned subsidiary. Acquisition cost: ¥1,871 million」
Shares held by non-controlling shareholders of ウィンテックポリマー were acquired, making it a wholly owned subsidiary and strengthening business operations. The acquisition cost was ¥1,871 million. - FY2016First statedAnnual report
「“Strategic M&A”」
M&A is explicitly identified as a means of growth, including for the purpose of acquiring new platforms.